Phase 2 Vitiligo Trial, Recruiting NCT07251595 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Condition: Vitiligo
Back to Vitiligo

Phase 2 Vitiligo Trial, Recruiting

NCT07251595
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must agree to and sign a consent form before the trial begins.
  • You must be between 18 and 75 years old (inclusive) on the day you sign the consent form — both men and women may apply.
  • You and your partner must agree not to try to have children during the study and for one month after finishing the medication, not to donate sperm or eggs, and to use effective birth control throughout; women must have a negative pregnancy test and must not be breastfeeding.
  • You must have been diagnosed with non-segmental vitiligo during the screening process.
  • You must agree to stop using all vitiligo treatments and any cosmetic products with therapeutic effects for the entire duration of the study.

Who may not be able to join:

  • People diagnosed with segmental, mixed, or undifferentiated vitiligo, or who have been diagnosed with any other skin pigmentation disorder.
  • People whose vitiligo patches on the face cover more than one-third of an area where the hair has also turned white.
  • People who have other active skin problems or skin infections during screening that could interfere with the treatment or results.
  • People with a history of certain infections or contagious/communicable diseases (confirm with trial site).
  • People with a known or suspected history of a weakened immune system.
  • People with tuberculosis (TB) or a latent (inactive) TB infection.
  • People who test positive for HIV, syphilis, hepatitis C, or hepatitis B.
  • People who currently have or have previously had any form of cancer.
  • People with abnormal thyroid function, a history of blood clot-related disease in the past 12 months, or a heart or stroke-related event requiring hospitalisation in the past 12 months.
  • People with serious problems affecting the heart, mind, kidneys, liver, immune system, digestive system, urinary system, nervous system, muscles and bones, skin, senses, hormones, or blood.
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • People who are known to be allergic to the study drug or any of its ingredients.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
5 December 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The percentage change in the facial vitiligo area score index (F-VASI) from the baseline.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov